We recently compiled a list of the 15 Small-Cap Stocks Poised to Outperform in 2025. In this article, we are going to take a ...
NEW YORK, NY / ACCESSWIRE / January 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...
NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an ...
NEW YORK, Jan. 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ: SGMO). Such investors are ...
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo Therapeutics, Inc. ("Sangamo Therapeutics, Inc.") (NASDAQ:SGMO) ...
RICHMOND, Calif., October 22, 2024--Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 ...
Sangamo Therapeutics regained development and commercialization rights for its hemophilia A candidate, giroctocogene fitelparvovec, after partner Pfizer conveyed its decision to terminate their ...
Sangamo will regain full rights to giroctocogene fitelparvovec, a gene therapy candidate for hemophilia A, after Pfizer ended ...
Research reports are not currently available for SGMO.
After hours: 7:58:02 pm GMT-5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback